Coivas review: published GLP-1 terms and evidence gaps

What Coivas says

These are attributed first-party merchant statements, not neutral medical evidence:

• Coivas describes the offered medication as compounded semaglutide.¹
• Coivas says a medical consultation with a licensed care provider is required.¹
• Coivas says price varies by medication and treatment plan.¹

The two-price conflict is the central Coivas question

Coivas displayed both “From $119 · Monthly” and “$149/mo all-in” on the captured merchant page. Those phrases are not interchangeable. One may refer to a starting tier, a particular medication configuration, a temporary offer, or a different bundle, but the evidence does not identify which explanation is correct. Calling either number the normal monthly cost would therefore manufacture certainty the source does not provide. A useful checkout review should preserve both statements, ask which medication and supply period each covers, and identify every service included in the amount due. Until Coivas supplies that mapping, the price conflict is not a minor footnote; it prevents a defensible recurring-cost comparison. This review leaves it open rather than selecting the more attractive number.

What the captured Coivas page can actually establish

The merchant page supports a narrow factual outline: Coivas presents compounded semaglutide, requires a medical consultation with a licensed care provider, and says cost varies with medication and treatment plan. It does not independently verify who dispenses the product, which states are served, how long one shipment lasts, whether titration changes price, or whether the consultation charge is part of either published amount. It also cannot establish medical suitability, expected weight change, or comparative quality. That separation matters because a polished enrollment page can describe a process without documenting the commercial and clinical details a buyer needs. Our assessment treats Coivas as the source for its own workflow statements and the FDA as the source for the compounded-drug regulatory boundary; neither source fills the missing contract terms.

Build a Coivas cost worksheet before entering checkout

A responsible comparison needs more than a headline rate. Ask Coivas to state the first amount charged, the recurring amount, the billing interval, the medication and supply duration, consultation or membership fees, shipping, laboratory requirements, refill rules, and any price change tied to dose or product selection. Record whether cancellation must occur before a cutoff and whether unused prepaid service is refundable. These questions do not imply that any undisclosed fee exists; they define the information missing from the captured page. Keep the $119 and $149 statements in separate worksheet rows until the company identifies the scope of each. If support supplies an answer, retain the date and exact wording because web pricing can change. Without that documentation, a cross-provider “monthly” comparison would mix unlike commercial units.

A consultation is a gate, not an outcome promise

Coivas’s consultation language indicates that a care-provider interaction is part of the merchant’s described pathway. It does not promise that a reader qualifies, that semaglutide will be prescribed, that compounded medication is appropriate, or that a particular result will follow. Before relying on the offer, a prospective patient can ask who conducts the consultation, what jurisdiction licenses apply, how follow-up questions are handled, which pharmacy would dispense an approved prescription, and what happens if no prescription is issued. Those are service-clarity questions, not medical advice. Product selection, prescribing, dosing, and monitoring remain matters for a licensed clinician. The practical consumer decision is whether Coivas discloses enough about the pathway and contract to justify proceeding to its consultation—not whether this page can predict treatment suitability or performance.

Pricing and billing

The Coivas homepage contained two conflicting statements: “From $119 · Monthly” for semaglutide and “$149/mo all-in.” We do not resolve this conflict. The amount due, cadence, inclusions, medication, and recurring terms must be verified before payment.¹

Clinician and prescription boundary

Coivas's published consultation requirement does not establish that any reader is eligible or that a prescription will be issued. Eligibility, prescribing, product selection, and treatment decisions belong to a licensed clinician; this review does not provide medical advice or dosing guidance.¹

Compounded-drug and FDA status

The source describes compounded semaglutide, which is distinct from FDA-approved branded semaglutide drugs. Compounded drugs are not FDA approved, and FDA does not premarket-review them for safety, effectiveness, or quality.²

What remains unknown

• The two published price statements conflict and are intentionally left unresolved.
• Medication source, dispensing pharmacy, state availability, exact eligibility rules, supply period, cancellation, and refund terms were not established by the captured page.
• No comparable independent public-review dataset was captured.
• No evidence supports an efficacy promise, outcome guarantee, or individualized recommendation.